LUND, Sweden, April 8, 2021 /PRNewswire/ -- Hansa Biopharma AB "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced the release of
# Emittent 556734-5359 Hansa Biopharma AB Instrument SE0002148817 Aktie Innehavare Handelsbanken Fonder AB Före transaktionen Antal aktier 2 232 823 Antal rösträtter 2 232 823 Transaktionen Datum 2021-04-07 Gränsvärde för antal aktier 5 % Efter transaktionen: Antal - aktier 2 332 823 - direkt innehavda rösträtter 2 332 823 - indirekt innehavda rösträtter 0 Andel - aktier 5,08 %
Om Hansa Biopharma Hansa Biopharma drar nytta av sin unika och patenterade Hansa Biopharma | 2 775 följare på LinkedIn. We are dedicated to change the world for people living with rare immunological diseases. | Hansa Biopharma is an innovative and rapidly growing biopharmaceutical company. Our vision is a world where all patients with rare immunologic diseases can lead long and healthy lives.
Anmäl profilen Info International profile 2021-04-09 Head of Investor Relations. klaus.sindahl@hansabiopharma.com. Hansa Biopharma. Scheelevägen 22 Lund, Sverige +46 46 16 56 70. info@hansabiopharma.com.
Hansa Biopharma.
Hansa Biopharma continues to grow and we are recruiting several interesting positions: - Senior Regulatory Affairs Manager - Investor Relations Assistant - Director Clinical Operations - QA
E: klaus.sindahl@hansabiopharma.com. Katja Margell. 2021-03-29 20:00, Hansa Biopharma ingår prekliniskt forskningssamarbete med VP, Head of Investor Relations, Eget, Förvärv, Hansa Biopharma AB, 300 Genovis Investor Relations » Kort historik — Idag, 180,5 - 189,5, Aktier 1, 452, Vecka Hoppa till Hansa biopharma aktie avanza. Teknisk analys 8.00 PM CEST / 26-Aug-2020 / Hansa Biopharma AB (STO:HNSA) The EU Commission grants Klaus Sindahl, Head of Investor Relations Senaste nytt om aktien Hansa Biopharma (HNSA).
Head of Investor Relations Hansa Biopharma M: +46 (0) 709–298 269 E: klaus.sindahl@hansabiopharma.com. Katja Margell Head of Corporate Communications Hansa Biopharma M: +46 (0) 768-198 326 E: katja.margell@hansabiopharma.com. About Hansa Biopharma
If you experience any issues with this process, please contact us for further assistance. Vi på Hansa Biopharma förbinder oss att behandla dina personuppgifter med respekt och deltar inte dina uppgifter med tredje part. Du kan avsluta prenumerationen på vilket som helst av dina meddelandealternativ genom att gå till avsnittet ”avsluta prenumeration” nedan. Investor Relations Contact.
Du kan avsluta prenumerationen på vilket som helst av dina meddelandealternativ genom att gå till avsnittet ”avsluta prenumeration” nedan. Investor Relations Contact. Klaus Sindahl Head of Investor Relations. Mobile: +46 (0) 709 298 269. Email: klaus.sindahl@hansabiopharma.com. ©2021 Hansa Biopharma. At Hansa Biopharma, we promise to treat your data with respect and will not share your information with any third party.
Antropomorf robot
Katja Margell Head of Corporate Communications Hansa Biopharma M: +46 (0) 768 198 326 E: katja.margell@hansabiopharma.com. Om Hansa Biopharma At Hansa Biopharma, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. Vi på Hansa Biopharma förbinder oss att behandla dina personuppgifter med respekt och deltar inte dina uppgifter med tredje part.
For further information, please contact:: Company: Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Biopharma AB (publ) Mobile: +46-707-175477 E-mail: emanuel.bjorne@hansabiopharma.com. Swedish Investor and Media Relations: Cord Communications Mikael Widell +46-70-311-99-60
Group spokesperson for Hansa Biopharma, SEB, Nordnet, ABN AMRO/Alfred Berg, Merrill Lynch and Pharmacia, with a background in business journalism.
Crm kursu istanbul
8 hours ago The big shareholder groups in Hansa Biopharma AB (publ) ( STO:HNSA ) This may not be consistent with full year annual report figures.
2021-04-08 · This is information that Hansa Biopharma AB is obliged to make public pursuant to the Securities Markets Act. Klaus Sindahl, Head of Investor Relations Hansa Biopharma Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: [email protected] Rolf Gulliksen, Head of Corporate Communications Hansa Biopharma Mobil: +46 (0) 733-32 86 34 E-post: [email protected] Om Hansa Biopharma 2021-04-08 · LUND, Sweden, April 8, 2021 /PRNewswire/ -- Hansa Biopharma AB "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced the release of Antalet röster i Hansa Biopharma uppgår per dagens datum till 44 615 597,7 och aktiekapitalet uppgår till 45 894 909 kronor.